An Overview of Prostate Brachytherapy

Opening of the article

Prostate cancer is the most common male cancer in the European Union and United States of America. The incidence of prostate cancer had been rising before PSA screening and will continue to rise with PSA testing having become more widespread and an ageing population. Prosate brachytherapy is an effective treatment for early stage prostate cancer with some centres reporting 10 year biochemical control rates of up to 87% for low risk patients. However the outcome depends on the technical quality of the implant and careful patient selection i.e.